Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

239.30 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biogen, Inc.

< Previous 1 2 3 4 5 6 Next >
Biogen Recognized As One of America's Most JUST Companies
Tags America's most JUST Companies Awards, Ratings & Rankings NASDAQ:BIIB
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen Recognized by Newsweek as one of America's Most Responsible Companies
Tags America's Most Responsible Companies Biogen Newsweek
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Johanna Jobin | The Innovator 25 North America 2021
Tags PRovoke Media INNOVATOR 25 AMERICAS 2021 NASDAQ:BIIB
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen Joins United Airlines Eco-Skies Alliance Program
Tags Environment NASDAQ:BIIB Biogen
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE clinical program evaluating the efficacy and safety of zuranolone for the treatment of... 
From Business Wire News Releases
Biogen Leads From the Top With Disability Inclusion
Tags Biogen NASDAQ:BIIB Disability Inclusion
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received zuranolone 50 mg once nightly for 14-days as their... 
From Business Wire News Releases
From Pause to Pride: A Mother's Journey
Tags NASDAQ:BIIB Diversity & Inclusion Biogen
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Youth Neurology Program: Building a More Diverse Neurology Workforce
Tags Biogen NASDAQ:BIIB Diversity & Inclusion
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Wanda Castro-Borrero: Carrying on Legacy of Care
Tags Biogen Diversity & Inclusion NASDAQ:BIIB
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15%
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
Tags Biogen NASDAQ:BIIB Awards, Ratings & Rankings
From 3BL Media: Corporate Social Responsibility, Energy and Health News
CEO Climate Alliance to World Leaders: We Support You in Taking Decisive Climate Steps at COP26
Tags Biogen Environment NASDAQ:BIIB
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen Launches Supplier Climate Action Program “Energize” With Leading Pharmaceutical Companies
Tags Supply Chain & the Circular Economy climate action Energize
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Introducing Biogen's 2021 Diversity, Equity & Inclusion Report
Tags Research, Reports & Publications NASDAQ:BIIB Diversity & Inclusion
From 3BL Media: Corporate Social Responsibility, Energy and Health News
A Letter From Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It's Time for Companies to Act Like the Climate Crisis Is a Health Crisis
Tags NASDAQ:BIIB Environment Biogen
From 3BL Media: Corporate Social Responsibility, Energy and Health News
MIT Collaborates With Biogen on Three-Year, $7 Million Initiative to Address Climate, Health, and Equity
Tags MIT Responsible Business & Employee Engagement NASDAQ:BIIB
From 3BL Media: Corporate Social Responsibility, Energy and Health News
MSM Students to Participate in Biogen's Summer Health Equity Fellowship Program
Tags NASDAQ:BIIB Biogen Health & Healthcare
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced their plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone, an... 
From Business Wire News Releases
Healthy Climate, Healthy Lives: Advancing Strategic Collaborations
Tags Harvard Environment Healthy Climate Healthy Lives
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Global Atopic Dermatitis Treatment Market Size Is Projected To Be Worth US$21.80 Billion By 2026
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Healthy Climate, Healthy Lives: Engaging Employees and Suppliers
Tags Responsible Business & Employee Engagement Biogen NASDAQ:BIIB
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychop
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE and NEST clinical development programs evaluating the efficacy and safety of zuranolone... 
From Business Wire News Releases
Healthy Climate, Healthy Lives: Fossil Fuel Free Operations
Tags Environment Biogen NASDAQ:BIIB
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative
Tags Health & Healthcare Environment Healthy Climate Healthy Lives
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
From GlobeNewswire News Releases
FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
From GlobeNewswire News Releases
FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
From GlobeNewswire News Releases
CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis
From GlobeNewswire News Releases
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.